Alaffia Health vs Cohere Health
Two payer side platforms that both design oversight carefully, pointed at different workflows. Alaffia is the payment integrity specialist: it digitises and cross references claims against the full record and policy, saves a reported $120 million, and is built for defensibility with anti black box logic, traceable citations, clinician sign off, and a SOC 2 Type II and HITRUST cert set. Cohere is the utilization management leader: prior authorization at network scale with the strongest evidence in this lane, and the clearest safety architecture in the category, stated as auto approve up to 85 percent, never auto deny, with clinicians deciding the rest. Both earn an A on autonomy, from different principles. The tiebreakers are scope and evidence against governance: Cohere has the fuller outcome record including provider measured satisfaction but a historical data bias gap graded C, while Alaffia's evidence is vendor reported at B. If your failure mode is payment integrity on high cost facility claims with maximally defensible determinations, start with Alaffia. If your failure mode is prior authorization at scale with a stated safety asymmetry, start with Cohere.
- Payment integrity is the specialism: OCR digitises unstructured bills and records, agents cross reference each claim against the full patient record and policy criteria, with a reported $120 million saved and over 20 percent average savings on high cost facility claims, graded A on AI centrality.
- Defensible by design: anti black box, clinical rationale and traceable citations on every recommendation, licensed clinician sign off, graded A on autonomy, plus a named certification set of SOC 2 Type II, HIPAA, and HITRUST, graded B on security.
- Precisely bounded to health plan claims operations and honest that it is specialised for the payer rather than a general tool, with roughly 30 day go live.
- Prior authorization at network scale with the strongest evidence in this lane: a reported 15 million plus submissions carried through the APIs, 47 million payer provider interactions annually, and provider satisfaction measured from the counterparty at 94 percent with an NPS of 67, graded A on clinical evidence.
- The safety asymmetry stated explicitly: the AI auto approves up to 85 percent in real time and does not auto deny, with the remainder reviewed by a clinician, the correct architecture for prior authorization and graded A on autonomy.
- Reaches the whole network, not just digital members: submissions accepted by phone, fax, and web as well as EHR integration, graded A on interoperability, with named plan relationships including Humana and Geisinger.
Side-by-Side
| Axis | A Alaffia Health |
C Cohere Health |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | — | — |
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | — |
| HIPAA and BAA Posture | — | — |
| Security Certifications and Trust Center | — | |
| FDA and Regulatory Status | — | — |
| AI Governance and Bias Disclosure | — | |
| EHR and Interoperability Depth | — | |
| Deployment Model and Data Residency | — | — |
| Commercial Transparency | ||
| Setting and Specialty Coverage | — |
Both are payer side, both grade A on AI centrality, and both grade A on autonomy but earn it differently: Alaffia through anti black box design and clinician sign off, Cohere through the auto approve, never auto deny asymmetry that is its entire safety argument. Cohere carries the stronger evidence, graded A, notably provider satisfaction measured from the counterparty rather than the buyer, which is meaningful evidence a payer tool is not simply obstructing care. Cohere's gap is governance, graded C, since models trained on historical authorization data can reinforce existing denial patterns and no bias evaluation was located. Alaffia's evidence is graded B, vendor reported without independent audit, and payment integrity savings are notoriously hard to attribute. Both are partially assessed, roughly six axes each. Neither publishes pricing, and both use return on investment framing that implies savings linked economics, so a buyer should establish whether compensation scales with denials or with cycle time, since those create opposite incentives at the clinician review checkpoint.